Zacks Research Issues Negative Forecast for TSE:BHC Earnings

Posted by Stuart Ham on Jun 26th, 2025

Bausch Health Companies Inc. (TSE:BHC – Free Report) – Zacks Research cut their Q2 2025 earnings per share (EPS) estimates for shares of Bausch Health Companies in a report issued on Monday, June 23rd. Zacks Research analyst R. Department now expects that the company will post earnings of $1.36 per share for the quarter, down from their previous estimate of $1.37. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q3 2025 earnings at $1.46 EPS, FY2025 earnings at $5.27 EPS, Q1 2026 earnings at $1.21 EPS, Q2 2026 earnings at $1.35 EPS, Q3 2026 earnings at $1.57 EPS, Q4 2026 earnings at $1.54 EPS, FY2026 earnings at $5.67 EPS, Q1 2027 earnings at $1.51 EPS and FY2027 earnings at $6.71 EPS.

Bausch Health Companies Trading Up 3.1%

BHC stock opened at C$8.74 on Thursday. The company has a current ratio of 1.19, a quick ratio of 0.58 and a debt-to-equity ratio of -1,831.94. Bausch Health Companies has a 12-month low of C$5.45 and a 12-month high of C$13.74. The stock has a market cap of C$2.27 billion, a price-to-earnings ratio of -12.79, a PEG ratio of 0.21 and a beta of 0.77. The business’s 50-day moving average is C$7.01 and its 200 day moving average is C$8.96.

Insider Buying and Selling

In other Bausch Health Companies news, Director John Paulson bought 1,782,030 shares of the firm’s stock in a transaction on Friday, June 13th. The shares were acquired at an average cost of C$8.14 per share, with a total value of C$14,501,803.73. In the last three months, insiders have bought 3,553,401 shares of company stock worth $27,087,675. Insiders own 11.28% of the company’s stock.

Bausch Health Companies Company Profile

(Get Free Report)

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.